GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:EGTX) » Definitions » Cyclically Adjusted Price-to-FCF

Egetis Therapeutics AB (OSTO:EGTX) Cyclically Adjusted Price-to-FCF : (As of Jan. 19, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF Chart

Egetis Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Egetis Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF falls into.



Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Egetis Therapeutics AB's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Egetis Therapeutics AB's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.211/132.3043*132.3043
=-0.211

Current CPI (Sep. 2024) = 132.3043.

Egetis Therapeutics AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -0.398 100.225 -0.525
201503 -0.440 99.950 -0.582
201506 -0.572 99.995 -0.757
201509 -0.327 100.228 -0.432
201512 -0.285 100.276 -0.376
201603 -0.213 100.751 -0.280
201606 -0.383 101.019 -0.502
201609 -0.257 101.138 -0.336
201612 -0.251 102.022 -0.326
201703 -0.222 102.022 -0.288
201706 -0.364 102.752 -0.469
201709 -0.178 103.279 -0.228
201712 -0.843 103.793 -1.075
201803 -0.282 103.962 -0.359
201806 -0.507 104.875 -0.640
201809 -0.311 105.679 -0.389
201812 -0.374 105.912 -0.467
201903 0.499 105.886 0.623
201906 -0.488 106.742 -0.605
201909 -0.605 107.214 -0.747
201912 -0.605 107.766 -0.743
202003 -0.636 106.563 -0.790
202006 -0.578 107.498 -0.711
202009 -0.421 107.635 -0.517
202012 -0.217 108.296 -0.265
202103 -0.195 108.360 -0.238
202106 -0.212 108.928 -0.257
202109 -0.172 110.338 -0.206
202112 -0.145 112.486 -0.171
202203 -0.185 114.825 -0.213
202206 -0.178 118.384 -0.199
202209 -0.199 122.296 -0.215
202212 -0.380 126.365 -0.398
202303 -0.326 127.042 -0.340
202306 -0.251 129.407 -0.257
202309 -0.373 130.224 -0.379
202312 -0.143 131.912 -0.143
202403 -0.186 132.205 -0.186
202406 -0.188 132.716 -0.187
202409 -0.211 132.304 -0.211

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Egetis Therapeutics AB  (OSTO:EGTX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines